Salvage lymphadenectomy in patients with lymphogenic prostate cancer progression after radical treatment: results of a multicenter study

Prostate cancer (PC) is one of the most challenging and pressing problems of modern oncourology because of high morbidity associated with the disease. The main methods of radical treatment of patients with localized and regional PC are radical prostatectomy and beam radiation therapy, external or brachytherapy. Nonetheless, the rate of biochemical progression of the disease after radical treatment remains high and averages 27–53 %. Of the utmost importance is determination of the tumor nidus which raises the marker level. Currently, in patients with distant metastases the only widely accepted treatment method is palliative hormonal therapy (HT). However, in majority of patients marker recurrence can be associated with so-called oligometastatic progression characterized by a minimal number of detectable metastases. Research shows that surgical treatment or beam radiation therapy in selected patients of this cohort allows to significantly increase the time until HT prescription, and in some cases to abandon it altogether. The article describes the results of surgical treatment of patients subjected to salvage lymphadenectomy for oligometastatic PC progression at three centers: P.A. Hertzen Moscow Oncology Research Institute, N.N. Petrov Research Institute of Oncology and Russian Research Center for Radiology and Surgical Technologies. In the multicenter study, short-term and longterm results of surgical treatment of 57 patients were evaluated. It was shown that in some patients, salvage lymphadenectomy can be an effective treatment option significantly lengthening the time until HT prescription, and in 23.4 % of patients it can lead to long-term (12 months) stabilization of the disease and 90 % decrease in prostate-specific antigen level compared to the initial pre-surgery level without any additional forms of therapy.

prostate cancer, oligometastases, lymphogenic progression, salvage lymphadenectomy, short-term treatment results, long-term treatment results, multicenter study

1. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России, 2016. 250 с. [Malignant tumors in Russia in 2014 (morbidity and fatality). Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: FGBU “Moskovskiy nauchno-issledovatel’skiy onkologicheskiy institute im. P.A. Gertsena” – filial FGBU “Natsional’nyy meditsinskiy issledovatel’skiy radiologicheskiy tsentr” Minzdrava Rossii, 2016. 250 p. (In Russ.)].

2. Han M., Partin A.W., Pound C.R. et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555–65. PMID: 11590814.

3. Simmons M.N., Stephenson A.J., Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007;51(5):1175–84. DOI: 10.1016/j.eururo.2007.01.015. PMID: 17240528.

4. Suardi N., Porter C.R., Reuther A.M. et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112(6):1254–63. DOI: 10.1002/cncr.23293. PMID: 18286530.

5. Roehl K.A., Han M., Ramos C.G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910–4. DOI: 10.1097/01.ju.0000134888.22332.bb. PMID: 15310996.

6. Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–7. PMID: 10235151.

7. Schweizer M.T., Zhou X.C., Wang H. et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 2013;24(11):2881–6. DOI: 10.1093/annonc/mdt335. PMID: 23946329.

8. Garcia J.R., Morenco C., Valls F. et al. Diagnostic performance of bone scintigraphy and 11C-choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol 2015;34(3):155–61. DOI: 10.1016/j.remn.2014.08.001. PMID: 25443648.

9. von Eyben F.E., Kairemo K. Metaanalysis of 11C-holine and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35(3):221–30. DOI: 10.1097/MNM.0000000000000040. PMID: 24240194.

10. Afshar-Oromieh A., Zechmann C.M., Malcher A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18Fcholine- based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41(1):11–20. DOI: 10.1007/s00259-013-2525-5. PMID: 24072344.

11. Власова О.П., Герман К.Э., Крылов В.В. и др. Новые радиофармпрепараты для диагностики и лечения метастатического рака предстательной железы на основе ингибиторов простатспецифического мембранного антигена. Вестник Российской академии медицинских наук 2015;70(3):360–6. [Vlasova O.P., German K.E., Krylov V.V. et al. New radiopharmaceuticals based on inhibitors of prostate-specific membrane antigen for metastatic prostate cancer diagnostics and treatment. Vestnik Rossiyskoy akademii meditsinskikh nauk = Bulletin of the Russian Academy of Medical Sciences 2015;70(3):360–6. (In Russ.)]. DOI: 10.15690/vramn.v70i3.1334.

12. Eiber M., Maurer T., Souvatzoglou M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET/ CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56(5):668–74. DOI: 10.2967/jnumed.115.154153. PMID: 25791990.

13. Osborne J.R., Akhtar N.H., Vallabhajosula S. at al. Prostate-specific membrane antigen-based imaging. Urol Oncol 2013;31(2):144–54. DOI: 10.1016/j.urolonc.2012.04.016. PMID: 22658884.

14. Rigatti P., Suardi N., Briganti A. et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by 11C-choline positron emission tomography/computed tomography. Eur Urol 2011;60(5):935–43. DOI: 10.1016/j.eururo.2011.07.060. PMID: 21840116.

15. Jilg C.A., Rischke H.C., Reske S.N. et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012;188(6):2190–7. DOI: 10.1016/j.juro.2012.08.041. PMID: 23083862.

16. Tilki D., Mandel P., Seeliger F. et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol 2015;193(2):484–90. DOI: 10.1016/j.juro.2014.08.096. PMID: 25180792.

17. Winter A., Henke R.P., Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urol 2015;15:10. DOI: 10.1186/s12894-015-0004-y. PMID: 25881245.

18. Suardi N., Karnes J., Joniau S. et al. Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases. J Urol 2013;189:e317–8.

19. Suardi N., Gandaglia G., Gallina A. et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow up of 5 years. Eur Urol 2015;67(2):299–309. DOI: 10.1016/j.eururo.2014.02.011. PMID: 24571959.